Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

205.57
-2.3100-1.11%
Post-market: 205.800.2300+0.11%19:58 EDT
Volume:2.27M
Turnover:464.85M
Market Cap:44.06B
PE:-23.04
High:207.02
Open:205.14
Low:200.53
Close:207.88
52wk High:224.31
52wk Low:37.88
Shares:214.34M
Float Shares:184.00M
Volume Ratio:0.96
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.91
PE(LYR):-34.55

Loading ...

Oppenheimer Adjusts Revolution Medicines PT to $195 From $165, Maintains Outperform Rating

MT Newswires Live
·
Jun 01

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $195 From $165

THOMSON REUTERS
·
Jun 01

Wedbush Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

TIPRANKS
·
Jun 01

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Oppenheimer Remains a Buy on Revolution Medicines (RVMD)

TIPRANKS
·
Jun 01

Summit drops as concerns over older patients cloud cancer trial data

Reuters
·
Jun 01

BUZZ-U.S. STOCKS ON THE MOVE -Revolution Medicines, FedEx, Xpeng

Reuters
·
Jun 01

MORNING BID AMERICAS-AI and 1984

Reuters
·
Jun 01

Revolution Medicines Pancreatic Cancer Trial Results Look Solid -- Market Talk

Dow Jones
·
Jun 01

Bellevue flags Merck-Kelun Sac-TMT Phase III OptiTROP-Lung05 data as top ASCO 2026 lung cancer catalyst

Reuters
·
Jun 01

Why doctors stood up and cheered mid-presentation for a historic pancreatic cancer treatment

Dow Jones
·
Jun 01

Stock Track | Revolution Medicines Soars 16.21% in Pre-Market on Breakthrough Pancreatic Cancer Trial Results

Stock Track
·
Jun 01

Movement Alert|Revolution Medicines Rises 15.38% in Pre-Market Trading, ASCO Phase 3 Pancreatic Cancer Data Far Exceeds Expectations

Market Focus
·
Jun 01

Stock Track | Revolution Medicines Soars 17.76% in Night Session on Positive Phase 3 Pancreatic Cancer Trial Results

Stock Track
·
Jun 01

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

Benzinga
·
Jun 01

Michael Yee Reiterates Buy Rating and Raises Price Target to $175 on Strong Pivotal Data and Launch Prospects for Daraxonrasib in Pancreatic Cancer

TIPRANKS
·
Jun 01

Movement Alert|Revolution Medicines Rises 7.95% Overnight, ASCO Conference RAS Inhibitor Pancreatic Cancer Data Fuels Market Optimism

Market Focus
·
Jun 01

Revolution Medicines announces results from Phase 3 RASolute 302 trial

TIPRANKS
·
Jun 01

Revolution Medicines Announces Asco Plenary Presentation Highlighting Unprecedented Results From Pivotal Phase 3 Rasolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

THOMSON REUTERS
·
May 31

CORRECTED-Revolution's pancreatic cancer drug doubles survival, boosts quality of life

Reuters
·
May 31